Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1640 of 5804
-
Old asthma drug shows promise for rare genetic disorder
Disease control OngoingPseudohypoparathyroidism is a genetic disorder with limited treatment options. Patients have early-onset obesity, short stature and increased risk of type 2 diabetes. This phase 2 clinical trial will test the efficacy of theophylline, a phosphodiesterase inhibitor, in pseudohypop…
Phase: PHASE2 • Sponsor: Vanderbilt University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Should we operate sooner on enlarged aortas? major trial aims to settle debate
Disease control Recruiting nowThe ascending aorta conducts blood from the heart to the rest of the body. The ascending aorta can become enlarged, and the risk of tearing and rupturing becomes higher with larger aorta. When the ascending aorta tears or ruptures, the risk dying is high even if surgery is done a…
Phase: NA • Sponsor: Ottawa Heart Institute Research Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Which blood thinner works best after heart device implant? new trial aims to find out
Disease control OngoingThe objective of the study is to compare short-term (8 weeks) anticoagulation therapy (DOAC) vs. antiplatelet therapy for the prevention of device thrombosis following transcatheter LAAC.
Phase: PHASE4 • Sponsor: Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Smaller incision, faster recovery? new trial tests heart bypass techniques
Symptom relief OngoingMICS CABG (Minimally invasive coronary surgery), where coronary artery bypass grafting (CABG) is completed through a small incision over the left chest, has evolved to become a safe and less invasive alternative to conventional sternotomy CABG. Several observational studies have …
Phase: NA • Sponsor: Ottawa Heart Institute Research Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Engineered immune cells take aim at HPV-Positive cancers
Disease control CompletedHuman papillomavirus infections 16 (HPV16) is known to be a high-risk factor to induce cervical cancers. To date, HPV16-related cervical cancer is still a major concern in developing countries where vaccination is not prevalent. Concurrent therapies for cervical cancers have limi…
Phase: PHASE1 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Three-Dose radiation breakthrough for breast cancer patients
Disease control CompletedThe investigators proposed approach allows them to deliver a low total dose of radiation to patients with low-risk, early-stage breast cancer which would further minimize the impact of adjuvant therapy. This work has the potential to revolutionize partial breast irradiation by al…
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Gene therapy for rare liver disease: Long-Term safety check
Disease control OngoingDetermine the long-term safety of DTX301 following a single intravenous (IV) dose in adults with late-onset ornithine transcarbamylase (OTC) deficiency.
Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for PNH patients: Long-Term drug safety confirmed
Disease control CompletedThis is an Open-label, Non-Randomized, Multi-Center Extension Study. Eligible subjects will have previously completed a pegcetacoplan study.
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Less fluid, better recovery? new trial tests approach in injured kids
Disease control Recruiting nowThis study is designed to help decide how much intravenous (IV) fluid should be given to pediatric trauma patients. No standard currently exists for managing fluids in critically ill pediatric trauma patients, and many fluid strategies are now in practice. For decades, trauma pat…
Phase: NA • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Experimental immune therapy for childhood brain cancer shows early safety signals
Disease control TerminatedIt is believed that the body's immune system protects the body by attacking and killing tumor cells. T-lymphocytes (T-cells) are part of the immune system and can attack when they recognize special proteins on the surface of tumors. In most patients with advanced cancer, T-cells …
Phase: PHASE1 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Simple home help and exercise may keep seniors independent after hospitalization
Symptom relief CompletedThis study evaluates whether the utilization of integrated health services such as help with medications, muscle strengthening, balance training, pain management and home modification interventions can help improve older adults' ability to sleep, balance, walk, and take care of t…
Phase: NA • Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jun 27, 2026 07:54 UTC
-
Diabetes drug and healthy habits tested to stop irregular heartbeat
Prevention OngoingProspective randomized open-label blinded endpoint (PROBE) 2x2 factorial study of metformin extended release up to 750 mg BID and lifestyle and risk factor modification (LRFM) in CIED patients with at least 1 ≥5 minute episode of AF over the prior 3 months. Randomization will be …
Phase: PHASE4 • Sponsor: Mina Chung, MD • Aim: Prevention
Last updated Jun 26, 2026 16:26 UTC
-
Experimental antibody drug tested for Tough-to-Treat leukemia
Disease control TerminatedThis phase I/II trial studies the side effects and best dose of ADCT-602 in treating patients with B-cell lymphoblastic leukemia that has come back or does not respond to treatment. Monoclonal antibodies, such as ADCT-602, may interfere with the ability of tumor cells to grow and…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug combo shows promise for tough brain cancer
Disease control CompletedThe purpose of this study is to test the safety of combined use of the study drugs, copanlisib and ibrutinib, in people with PCNSL.
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug cocktail shows promise for Hormone-Sensitive uterine cancer
Disease control CompletedThe purpose of this study is to determine the effectiveness of the combination of abemaciclib and fulvestrant in treating this type of cancer and to determine the types and severity of side effects caused by treatment with abemaciclib and fulvestrant.
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Donor vaccine may shield transplant patients from dangerous virus
Prevention OngoingThis phase II trial studies how well multi-peptide CMV-modified vaccinia Ankara (CMV-MVA Triplex) vaccination of stem cell donors works in preventing cytomegalovirus (CMV) viremia in participants with blood cancer undergoing donor stem cell transplant. Giving a vaccine to the don…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Prevention
Last updated Jun 27, 2026 08:03 UTC
-
New drug targets genetic weakness in Hard-to-Treat cancers
Disease control OngoingThis phase II MATCH treatment trial tests how well JNJ-42756493 (erdafitinib) works in treating patients with tumors that have more copies of the FGFR gene than is normal (amplification). Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug cocktail targets rare, aggressive kidney cancer
Disease control OngoingThis phase II trial studies how well ixazomib, gemcitabine, and doxorubicin work in treating patients with kidney cancer that has spread to other places in the body (locally advanced or metastatic). Ixazomib may stop the growth of tumor cells by blocking some of the enzymes neede…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug combo shows promise for leukemia patients
Disease control CompletedThis phase Ib trials studies the side effects of daratumumab and ibrutinib and how well they work in treating patients with symptomatic chronic lymphocytic leukemia. Monoclonal antibodies, such as daratumumab, may interfere with the ability of cancer cells to grow and spread. Ibr…
Phase: PHASE1 • Sponsor: Jennifer Woyach • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy drug avelumab takes on rare penile cancer
Disease control OngoingThis is a phase 2 study whose purpose is see how useful investigational drug, avelumab, is in patients with locally advanced or metastatic penile cancer who are unfit for or progressed on platinum-based chemotherapy. The usefulness of avelumab in this study population will be de…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC